WO2006049250A1 - 眼内移行性促進水性点眼剤 - Google Patents
眼内移行性促進水性点眼剤 Download PDFInfo
- Publication number
- WO2006049250A1 WO2006049250A1 PCT/JP2005/020302 JP2005020302W WO2006049250A1 WO 2006049250 A1 WO2006049250 A1 WO 2006049250A1 JP 2005020302 W JP2005020302 W JP 2005020302W WO 2006049250 A1 WO2006049250 A1 WO 2006049250A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino
- acid
- bromobenzoyl
- concentration
- aqueous eye
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to an eye containing 2 amino-3- (4 bromobenzoyl) phenol acetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof as an active ingredient.
- Intraocular aqueous ophthalmic solution once per day with enhanced internalization and extended maintenance time of 2-amino-3- (4 bromobenzol) phenylacetic acid in the aqueous humor.
- the present invention also provides an organic amine or a salt thereof as an aqueous eye drop containing 2-amino-3- (4 bromobenzoyl) phenol acetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof as an active ingredient.
- 2-Amino-3- (4-bromobenzoyl) phenol acetic acid (generic name: bromfenac) is a compound represented by the following formula (I), and is an acidic non-steroidal anti-inflammatory agent.
- examples of the promotion of drug absorption into ocular tissues or the improvement of drug retention in the eye include, for example, corneal penetration of atenolol, carteolol, tirisolol and timolol, whose strength purine acid is a j8 blocker.
- Examples of enhanced sex in vitro experiments see Non-patent Document 1), fatty acids having 3 to 7 carbon atoms extended the retention time of ⁇ -blockers in ocular tissues (see Patent Document 2), cabronic acid
- An example of corneal permeability of bunazosin hydrochloride, which is a sympathetic nerve alpha-receptor blocker, in combination with strength prillic acid or strength purine acid Patent Literature
- salt benzalco-um used as a preservative in ophthalmic solutions not only promotes corneal permeability of FITC (fluorescein isothiocyanate) -dextran, but also slightly promotes conjunctival permeability. (See Non-Patent Document 2).
- organic amines such as trometamol are used as buffers in ophthalmology.
- Organic amines such as trometamol also stabilize ophthalmic solutions, solubilize, reduce irritation, preserve Also used to improve efficacy.
- tromethamine or 4 (2-hydroxyethyl) 1 (2-sulfoethyl) piperazine is added to an ophthalmic solution containing pranoprofen. It is disclosed (see Patent Document 4).
- a method for making a sulfa drug soluble and improving its antiseptic effect by incorporating an alkanolamine such as monoethanolamine, diethanolamine, or triethanolamine into an ophthalmic solution containing the sulfa drug See Patent Document 5, Patent Document 6, and Patent Document 7).
- Diclofenac sodium ophthalmic solution containing trometamol or a homologue having 10 or less carbon atoms as a preservative and stabilizer is also disclosed (see Patent Document 8 and Patent Document 9).
- Non-patent document 1 H. Sasaki et al., Pharmaceutical Research, 1995, No. 2, No. 8, p. 1146-1150
- Non-patent document 2 H. Sasaki, Journal of Pharmacy ana Pharmacology, 199 5, 47, 9, p. 703-707
- Patent Document 1 Japanese Patent Laid-Open No. 2-124817 (Patent No. 2683676)
- Patent Document 2 Pamphlet of International Publication No.99Z22715
- Patent Document 3 JP-A-63-301822 (Patent No. 2563336)
- Patent Document 4 JP-A-8-291065 (Patent No. 3170619)
- Patent Document 5 Japanese Patent Publication No. 1-29170
- Patent Document 6 JP 59-89616
- Patent Document 7 Japanese Patent Laid-Open No. 61-12617
- Patent Document 8 Japanese Patent Laid-Open No. 62-242617
- Patent Document 9 Japanese Patent Laid-Open No. 62-242618 Disclosure of the invention
- the present invention promotes the intraocular transfer of 2-amino-3- (4 bromobenzoyl) phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof after instillation, and treats inflammatory diseases Therefore, it is an object of the present invention to provide an eye drop-type aqueous eye drop in which an effective concentration of 2-amino-3- (4 bromobenzoyl) phenylacetic acid is maintained in anterior aqueous humor.
- the present invention provides the following.
- An aqueous eye drop containing 2-amino-3- (4 bromobenzoyl) phenol acetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof is administered once a day.
- a method for treating an inflammatory disease of the external or anterior segment characterized by maintaining a therapeutically effective concentration of 2-amino-3- (4 bromobenzoyl) phenol acetic acid in the anterior aqueous humor for at least 24 hours after administration ,
- the concentration of 2-amino-3- (4 bromobenzoyl) phenol acetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof in aqueous eye drops should be 0.01 to 0.5 wZv%.
- the organic amine is at least one selected from the group consisting of amino acids, alkanolamines, diamines, piperazines and aminoaminosulfonic acids (2 ) Described method,
- An aqueous eye drop containing 2-amino-3- (4 bromobenzoyl) phenol acetic acid or a pharmaceutically acceptable salt thereof or a hydrate thereof contains an organic amine or a salt thereof; Amine or its salt content power 2 -amino 3- (4 bromobenzoyl) phenol acetic acid contained in aqueous ophthalmic solution Ophthalmic Z Water aqueous ophthalmic solution with an amount of 0.7 to 4 is applied.
- the present invention also provides the following inventions.
- the concentration of 2-amino-3- (4 bromobenzoyl) phenol acetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof in an aqueous eye drop is 0.01 to 0.5 wZv%.
- An aqueous eye drop containing 2-amino-3- (4 bromobenzoyl) phenol acetic acid or a pharmaceutically acceptable salt thereof or a hydrate thereof contains an organic amine or a salt thereof,
- the content of the amine or a salt thereof is an amount that makes the octanol Z water partition coefficient of 2-amino-3- (4 bromobenzoyl) phenol acetic acid contained in the aqueous eye drop 0.7 to 4. (13) or the aqueous eye drop according to (14),
- the present invention also provides the following inventions.
- An aqueous ophthalmic solution containing 2-amino-3- (4 bromobenzoyl) phenol acetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof is administered once a day.
- the concentration of 2-amino-3- (4 bromobenzoyl) phenol acetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof in the aqueous eye drop is 0.01 to 0.5 wZv%.
- the amount of organic amine or its salt used is an amount that makes the octanol Z water partition coefficient of 2-amino-3- (4 bromobenzoyl) phenol acetic acid contained in aqueous eye drops 0.7 to 4.
- treatment with 2-amino-3- (4 bromobenzoyl) phenolacetic acid is carried out for at least 24 hours after administration by simply instilling the aqueous eye drop of the present invention once a day. Effective concentrations can be maintained in the anterior aqueous humor.
- an organic amine or a salt thereof to an aqueous eye drop containing 2-amino-3- (4bromobenzoyl) phenol acetic acid or a pharmaceutically acceptable salt thereof or a hydrate thereof.
- the aqueous eye drop of the present invention is advantageously used as an eye drop once a day for the treatment of blepharitis, conjunctivitis, scleritis, postoperative inflammation or uveitis.
- the pharmacologically acceptable salt of 2-amino-3- (4 bromobenzoyl) phenol acetic acid used in the aqueous eye drop of the present invention is not particularly limited, and examples thereof include sodium salt and potassium salt. Examples thereof include alkaline earth metal salts such as alkali metal salts, calcium salts and magnesium salts. Of these salts, sodium salt is particularly preferred. 2 Amino-3- (4 bromobenzoyl) phenol acetic acid and its pharmacologically acceptable The acceptable salt can be appropriately produced by, for example, the method described in JP-A-52-23052 (corresponding US Pat. No. 4,045,576) or a method analogous thereto.
- the hydrate is not particularly limited, and examples thereof include 1Z2 hydrate, monohydrate, and 3Z2 hydrate, and 3Z2 hydrate is particularly preferable.
- the content (concentration range) of 2-amino-3- (4 bromobenzoyl) phenol acetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof is usually About 0.01w / v% to 0.5w / v%, preferably about 0.05w / v% to 0.2w / v%, particularly preferably about 0.1w / v% to 0.2w / v It is preferable to increase or decrease appropriately according to the purpose of use and the degree of indication symptoms.
- the aqueous ophthalmic solution of the present invention comprises 2 amino-3- (4 bromobenzoyl) phenol acetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, which promotes the transition to the ocular tissue.
- Organic amines or their salts can be used to maintain a therapeutically effective concentration of 2-amino-3- (4 bromobenzoyl) phenolacetic acid that has migrated into the chamber for at least 24 hours after instillation in anterior chamber water.
- the measurement of octanol Z water partition coefficient is based on OECD Test Guideline (OE CD Board decision “C (81) 30 Final Attachment 1”) 107 or Japanese Industrial Standard Z7260-107 (2000 ) “Measurement of distribution coefficient (1-octanol / water) is preferably measured according to the flask shaking method”. Specifically, it can be measured by the test method of Experimental Example 3 below.
- the organic amine or a salt thereof is a partition coefficient of 2 amino-3- (4 bromobenzoyl) phenylacetic acid in the test method of Experimental Example 3 below (measurement of water partition coefficient of otatanol Z). Is preferably about 0.7-4.
- organic amines or salts thereof include amino acids (for example, arginine, histidine, aspartic acid, glutamic acid, serine, threonine, cystine, ferrolanine, and isoleucine), alkanolamines (for example, monoethanolamine) , Diethanolamine, triethanolamine, trometamol, etc.), piperazines (eg HEPES (2— [4— (2— Hydroxy ethyl) — 1— piperadmylj ethansulf onic acid), 1, 4 His, 2—sulfoethyl) ) Piperazine, etc.), diamines (eg, ethylenediamine, trimethyle) And N, N, N-bis (3-sulfopropyl) ethylenediamine, etc.), aminoalkyl sulfonic acids (eg, aminomethylsulfonic acid, aminoethylsulfonic acid, etc.). Of these, alkanolamines or aminoalkyl sul
- Examples of salts of organic amines include inorganic acid salts (eg, hydrochloride, nitrate, sulfate, sulfite, phosphate or hydroiodide), organic acid salts (eg, acetate, formate) , Oxalate, lactate, dalconate, adipate or alkyl phosphate), inorganic base (eg sodium salt, calcium salt, magnesium salt etc.) or organic base (eg ammonium salt etc.) ) And the like.
- inorganic acid salts eg, hydrochloride, nitrate, sulfate, sulfite, phosphate or hydroiodide
- organic acid salts eg, acetate, formate
- Oxalate lactate, dalconate, adipate or alkyl phosphate
- inorganic base eg sodium salt, calcium salt, magnesium salt etc.
- organic base eg ammonium salt etc.
- organic amines or salts thereof may be used singly or in combination of two or more.
- the content (concentration range) of the organic amine or a salt thereof is determined according to the test method of Experimental Example 3 (measurement of octanol Z water partition coefficient) shown below: 2 amino-3- (4 bromobenzoyl) )
- concentration range where the partition coefficient of phenylacetic acid is about 0.7 to 4 varies depending on the type of compound used, but usually the lower limit is about 0.01 w / v% and the upper limit is about 5. Ow / It is about v%.
- the content thereof is about 0.35 w / v% at the lower limit, preferably about 0.4 w / v%, about 5 w / v% at the upper limit, Preferably it is about 2 w / v%.
- the content is lower limit of about 0.15 w / v%, preferably about 0.2 w / v%, upper limit of about 0.95 w / v%, preferably about 0.9 w. It is about / v%.
- the content is about 0.05 w / v% at the lower limit, preferably about 0.1 w / v%, about 5 w / v% at the upper limit, preferably about 2 w / v%.
- the content is about 0.05 w / v% at the lower limit, preferably about 0.1 w / v%, about 5 w / v% at the upper limit, preferably about 2 w / v%. It is.
- aminoalkylsulfonic acid When aminoalkylsulfonic acid is used, its content is about 0.05 w / v% at the lower limit, preferably about 0.1 w / v%, about 5 w / v% at the upper limit, preferably about 2 w / v%, more preferred. Or about lw / v%. More specifically, in particular, when aminoethylsulfonic acid is used, its content is about 0.05 w / v% at the lower limit, preferably about 0.1 wwv, preferably about 5 w / v%, preferably Is about 2w / v%, more preferably about lwZv%. Trometa When the molding is used, the content is about 0.15 wZv% at the lower limit, preferably about 0.2 wZv%, and about 0.95 wZv%, preferably about 0.9 wZv%.
- the aqueous eye drop of the present invention usually has a pH of about 5.0 to 9.0, preferably using a pH adjuster (eg hydrochloric acid, sodium hydroxide, phosphoric acid or acetic acid). It is adjusted to about 6.5 to 8.5, more preferably about 7.0 to 8.0.
- a pH adjuster eg hydrochloric acid, sodium hydroxide, phosphoric acid or acetic acid. It is adjusted to about 6.5 to 8.5, more preferably about 7.0 to 8.0.
- additives usually used in eye drops for example, isotonic agents (for example, sodium chloride salt, potassium salt salt, glycerin, concentrated glycerin, mannitol, Sorbitol, boric acid, glucose or propylene glycol, etc.), buffer (eg phosphate buffer, acetate buffer, borate buffer, carbonate buffer, citrate buffer, Tris buffer, glutamic acid or epsilon aminocapron) Acid), water-soluble polymers [for example, povidone (povidone K30, povidone ⁇ 25, etc.), polybulu alcohol, sodium polyacrylate, etc.], surfactants (for example, alkyl aryl polyether alcohol type polymers (for example, Tyloxapol, etc.), polyethylene glycol fatty acid esters (eg, monostearic acid polyester) Lenglycol, etc.), polysorbate 80, polyoxyethylene hydrogenated castor oil, etc.],
- isotonic agents for example, sodium chloride salt, potassium salt salt,
- the amount of these additives to be added depends on the kind and use of the additive to be added.
- a tonicity agent that only needs to be added at a concentration that can achieve the purpose of the strength additive usually has an osmotic pressure ratio. It can be added to about 0.8 to 1.2.
- the buffer is about 0.01 to 2 wZv%
- the water-soluble polymer is about 0.1 to 10 wZv%
- the surfactant is about 0.01 to 0.5 wZv%
- the preservative is It is preferable to add about 0.0005-0. 5 wZv% and about 0.001 to lwZv% of stabilizer! /.
- the aqueous eye drop of the present invention may appropriately contain other same or different medicinal ingredients as long as the object of the present invention is not violated.
- Examples of the same kind of medicinal ingredients include pranoprofen, fluorometholone, pred-zolone acetate, dexamethasone, or sodium azulene sulfonate.
- Examples of other medicinal ingredients include antibacterial ingredients (e.g., ofloxacin, gatifloxacin, levofloxacin, ofloxacin, galenoxacin mesylate, pazufloxacin mesylate, tosfloxacin tosylate, norfloxacin, levofloxacin, lomefloxacin hydrochloride, cefmenoxime hydrochloride, Cole, sulfisoxazole, sulbenicillin sodium, tobramycin, pimaricin, etc.), anti-allergic ingredients (for example, ketotifen fumarate, sodium cromoglycate, levocabastine hydrochloride, pemirolast potassium, chlorfelamine maleate, ibudilast, diflofu) Enac sodium, etc., corneal disease therapeutic ingredients (eg hyaluronic acid or its salts), anti-glaucoma ingredients (eg timolo maleate) Dipivefrin hydrochloride, bunazo
- the aqueous eye drop of the present invention can be produced by, for example, dissolving the above-mentioned components in an aqueous medium according to a known method, for example, the method described in the 14th revised Japanese Pharmacopoeia, General Rules for Preparations.
- aqueous medium used include purified water, water for injection, and sterilized purified water.
- the aqueous eye drop of the present invention can also be provided as a preservative-free type (disposable type) eye drop.
- Disposable eye drops are preferably stored in a sealed container that can be opened at the time of use.
- the aqueous eye drop of the present invention is a disposable eye drop, it is possible to produce an eye drop free from the risk of contamination by microorganisms even if it does not contain a preservative.
- the present invention also provides the therapeutic effect of 2-amino-3- (4 bromobenzoyl) phenol acetic acid in ocular tissues, particularly in the anterior chamber or anterior ocular tissue, characterized by instilling the above aqueous eye drops A method for extending the concentration maintenance time is provided.
- the therapeutically effective concentration of 2-amino-3- (4 bromobenzoyl) phenolacetic acid is the intraocular after anterior chamber puncture, as shown in Experimental Example 2 below (medicinal efficacy test in Usagi anterior chamber puncture model). A concentration that can suppress inflammation by at least about 25%. Usagi's anterior chamber puncture The concentration of 2-amino-3- (4 bromobenzoyl) furacetic acid in the anterior chamber, which can suppress later intraocular inflammation by at least about 25% or more, is about 1.5 ngZmL or more.
- the concentration of the drug in the anterior chamber can be measured by the HPLC method shown in the following Experimental Example 1 (Aqueous humor drug transfer test) for the anterior chamber fluid collected at the time of anterior chamber puncture.
- the aqueous eye drop of the present invention can prolong the maintenance time of a therapeutically effective concentration of 2-amino-3- (4 bromobenzoyl) phenylacetic acid in ocular tissue, particularly in the anterior chamber or anterior segment tissue.
- the prolongation of the therapeutically effective concentration maintenance time means that when the eye drop containing 2 amino-3- (4 bromobenzoyl) phenylacetic acid or a salt thereof is instilled once, the therapeutic effective concentration maintenance time in the anterior aqueous humor is about Allowing more than 12 hours means that preferably the therapeutically effective concentration maintenance time is at least about 24 hours.
- the aqueous ophthalmic solution of the present invention can maintain a therapeutically effective concentration of 2-amino-3- (4-bromobenzoyl) phenylacetic acid in ocular tissues, particularly in the anterior chamber or anterior ocular tissues, for at least 24 hours after ophthalmic administration. Therefore, the number of eye drops applied to the aqueous eye drop can be once a day.
- the dosage of the aqueous eye drop of the present invention is, for example, 2 drops of amino 3- (4 bromobenzoyl) phenylacetate 3Z2 hydrate 0. lwZv% of the aqueous eye drop of the present invention, blepharitis, When used for the treatment of conjunctivitis, scleritis, postoperative inflammation, or uveitis, 1 to several (2 to 5) drops for adults should be instilled once a day. The number of instillations can be increased or decreased as appropriate depending on the symptoms.
- the filtrate was used as an HPLC measurement sample, and a 2-amino-3- (4-bromobenzoyl) phenylacetic acid concentration was measured using a high performance liquid chromatograph (Shiseido NanospaceSI-1) under the following HPLC conditions.
- UV absorptiometer (measurement wavelength 266nm)
- Phosphate buffer (PH7.3) 50 mM hydrogen diammonium phosphate buffer (pH 7.3) containing 5 mM tetrabutyl ammonium chloride [0040] [Table 2]
- the concentration of 2-amino-3- (4 bromobenzoyl) phenolacetic acid in aqueous humor 2 hours after instillation is approximately 1.2 times higher for formulations containing trometamol and about 1 for formulations containing aminoethylsulfonic acid compared to the eye drops of Formula 1. Increased 6 times.
- Heparin sodium heparin, Ajinomoto was administered 1 OOOUZkg 30 minutes before puncture of the anterior chamber.
- a disposable disposable intraocular injection needle (30G X 3Z4, Nipro physician) is bent and punctured from the central side of the cornea approximately 1 mm from the limbus at 1 o'clock limbus. 80 ⁇ u L of water was collected (anterior chamber puncture).
- Measurement of anterior chamber flare (phot on count / msec) was performed 30 minutes after anterior chamber puncture using a laser flare cell meter (FC-1000, Kowa).
- FC-1000 laser flare cell meter
- the inflammation inhibition rate after anterior chamber puncture was calculated from the following equation.
- Inhibition rate (%) (Average atrial flare value in the Control group) Average atrial flare value in the test substance administration group) (Average atrial flare value in the Control group) X 100
- the calculated inflammation suppression rate after anterior chamber puncture is shown in Table 5.
- Ami The inhibition rate after 24 hours of the no-ethylsulfonic acid additive-free formulation (Formulation 4) was 0.3%.
- the inhibition rate of Formula 5 containing aminoethylsulfonic acid was 25.5%, and the inhibition rate of Formula 6 was 73.9%.
- the concentration of 2-amino-3- (4-bromobenzoyl) phenylacetic acid in each layer was measured with a high performance liquid chromatograph (Shimadzu Corporation, LC-10AD).
- LC-10AD high performance liquid chromatograph
- dissolved was used.
- UV absorptiometer (measurement wavelength: 266nm)
- Mobile phase diammonium hydrogen phosphate 1. Dissolve 98 g in 750 mL of water, adjust phosphoric acid to pH 7.3, and then mix 250 mL of acetonitrile.
- Octanol Z water partition coefficient was calculated by the following formula.
- Octanol Z water partition coefficient (2-amino-3- (4 bromobenzol) phenolacetic acid concentration in octanol layer) / (2-amino-3- (4 bromobenzoyl) phenylacetic acid concentration in aqueous layer)
- the above components were mixed by a conventional method to obtain an aqueous eye drop.
- the above components were mixed by a conventional method to obtain an aqueous eye drop.
- PH 7.5 Mix the above ingredients by a conventional method to make an aqueous eye drop.
- the above components are mixed by a conventional method to obtain an aqueous eye drop.
- the above components are mixed by a conventional method to obtain an aqueous eye drop.
- the above components are mixed by a conventional method to obtain an aqueous eye drop.
- the above components are mixed by a conventional method to form a disposable aqueous eye drop.
- the above components are mixed by a conventional method to obtain an aqueous eye drop.
- an aqueous ophthalmic solution containing 2-amino-3- (4 bromobenzoyl) phenol acetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof is added to an organic amine, in particular, By combining aminoethylsulfonic acid or trometamol or their salts, 2 amino-3- (4-bromobenzoyl) phenol acetic acid or its pharmacology Of 2-amino-3- (4 bromobenzoyl) phenol at a concentration effective to treat inflammatory diseases for at least 24 hours after instillation of pharmaceutically acceptable salts or their hydrates.
- An aqueous ophthalmic solution in which ruacetic acid is maintained in anterior aqueous humor can be provided.
- the aqueous eye drop of the present invention is advantageously used as a once-daily eye drop for the treatment of blepharitis, conjunctivitis, scleritis, postoperative inflammation or uvea, for example.
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020137015731A KR20130080061A (ko) | 2004-11-05 | 2005-11-04 | 안구 내 이행성 촉진 수성 점안제 |
MX2007001172A MX2007001172A (es) | 2004-11-05 | 2005-11-04 | Gotas acuosas para ojos que promueven la penetracion intraocular. |
US10/568,418 US20070021507A1 (en) | 2004-11-05 | 2005-11-04 | Aqueous eye drops with accelerated intraocular migration |
PL05805529T PL1808170T3 (pl) | 2004-11-05 | 2005-11-04 | Wodne krople do oczu z przyśpieszoną migracją wewnątrzgałkową |
KR1020067022310A KR101312740B1 (ko) | 2004-11-05 | 2005-11-04 | 안구 내 이행성 촉진 수성 점안제 |
CA2560559A CA2560559C (en) | 2004-11-05 | 2005-11-04 | Aqueous intraocular penetration-promoting eye drop |
EP05805529A EP1808170B1 (en) | 2004-11-05 | 2005-11-04 | Aqueous eye drops with accelerated intraocular migration |
CN2005800259636A CN1993118B (zh) | 2004-11-05 | 2005-11-04 | 促进眼内渗透性的水性滴眼剂 |
JP2006542445A JP4933897B2 (ja) | 2004-11-05 | 2005-11-04 | 眼内移行性促進水性点眼剤 |
AT05805529T ATE520394T1 (de) | 2004-11-05 | 2005-11-04 | Wässrige augentropfen mit beschleunigter intraokularer migration |
US13/332,827 US8299124B2 (en) | 2004-11-05 | 2011-12-21 | Aqueous intraocular penetration-promoting eye drop |
US13/616,810 US8518996B2 (en) | 2004-11-05 | 2012-09-14 | Aqueous intraocular penetration-promoting eye drop |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004322569 | 2004-11-05 | ||
JP2004-322569 | 2004-11-05 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/568,418 A-371-Of-International US20080007713A1 (en) | 2004-04-29 | 2005-04-26 | Optical Input Device and Method of Measuring Relative Movement of an Object and an Optical Input Device |
US13/332,827 Division US8299124B2 (en) | 2004-11-05 | 2011-12-21 | Aqueous intraocular penetration-promoting eye drop |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006049250A1 true WO2006049250A1 (ja) | 2006-05-11 |
Family
ID=36319250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/020302 WO2006049250A1 (ja) | 2004-11-05 | 2005-11-04 | 眼内移行性促進水性点眼剤 |
Country Status (11)
Country | Link |
---|---|
US (3) | US20070021507A1 (ja) |
EP (1) | EP1808170B1 (ja) |
JP (1) | JP4933897B2 (ja) |
KR (2) | KR101312740B1 (ja) |
CN (1) | CN1993118B (ja) |
AT (1) | ATE520394T1 (ja) |
CA (1) | CA2560559C (ja) |
ES (1) | ES2369089T3 (ja) |
MX (1) | MX2007001172A (ja) |
PL (1) | PL1808170T3 (ja) |
WO (1) | WO2006049250A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010190837A (ja) * | 2009-02-20 | 2010-09-02 | Kurabo Ind Ltd | logPの決定方法、および該方法に使用される二相系溶媒 |
CN101313899B (zh) * | 2007-06-01 | 2012-02-29 | 北京德众万全药物技术开发有限公司 | 一种含有溴芬酸钠的眼用药物组合物 |
WO2012099142A1 (ja) * | 2011-01-18 | 2012-07-26 | 千寿製薬株式会社 | 保存効力を有するブロムフェナク水性液剤組成物 |
JP2012224628A (ja) * | 2011-04-08 | 2012-11-15 | Rohto Pharmaceutical Co Ltd | ブロムフェナク含有組成物 |
JP2012532091A (ja) * | 2009-06-30 | 2012-12-13 | 参天製薬株式会社 | ラタノプロストのバイオアベイラビリティを向上させる方法 |
JP2014510018A (ja) * | 2010-12-15 | 2014-04-24 | シェンヤン、シンチ、ファーマシューティカル、カンパニー、リミテッド | ブロムフェナク有機塩、ならびにその製造方法、組成物および使用 |
WO2015046281A1 (ja) * | 2013-09-26 | 2015-04-02 | 参天製薬株式会社 | 安定化された2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸含有水性組成物 |
CN110461350A (zh) * | 2017-02-21 | 2019-11-15 | 缇尔索卢森公司 | 稳定的肽组合物 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI465236B (zh) * | 2007-03-13 | 2014-12-21 | 參天製藥股份有限公司 | 含有吡諾克辛之懸浮型水性液劑 |
WO2009117086A2 (en) * | 2008-03-17 | 2009-09-24 | Cardiac Pacemakers, Inc. | Deactivation of intermittent pacing therapy |
EA201591910A1 (ru) * | 2013-06-19 | 2016-05-31 | Сентисс Рисерч Центр | Стабильный раствор бромфенака |
CN111743858B (zh) * | 2019-03-29 | 2023-06-27 | 天津药业研究院股份有限公司 | 一种溴芬酸钠的药物组合物 |
CN112823784B (zh) * | 2019-11-20 | 2022-09-16 | 湖北远大天天明制药有限公司 | 吡诺克辛钠滴眼液以及用于眼部给药的溶液 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02124817A (ja) * | 1988-01-27 | 1990-05-14 | Senju Pharmaceut Co Ltd | 局所投与用炎症性疾患治療剤 |
WO1996019211A1 (fr) * | 1994-12-19 | 1996-06-27 | Taisho Pharmaceutical Co., Ltd. | Gouttes de collyre aux liposomes |
JPH08291065A (ja) * | 1995-04-20 | 1996-11-05 | Santen Pharmaceut Co Ltd | 有機アミンを配合したプラノプロフェン点眼液 |
JPH11335301A (ja) * | 1998-05-21 | 1999-12-07 | Nof Corp | 眼科用製剤 |
JP2002114711A (ja) * | 2000-10-12 | 2002-04-16 | Lion Corp | 外用剤組成物 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2860160A (en) * | 1956-11-19 | 1958-11-11 | Gen Aniline & Film Corp | Preparation of aminoalkyl acids and derivatives thereof |
JPS5989616A (ja) | 1982-11-15 | 1984-05-23 | Lion Corp | 点眼液 |
JPS5989617A (ja) | 1982-11-15 | 1984-05-23 | Lion Corp | 点眼液 |
JPS6112617A (ja) | 1984-06-27 | 1986-01-21 | Lion Corp | 点眼液 |
US4563291A (en) * | 1984-07-20 | 1986-01-07 | Halliburton Company | Method of preparation of substituted amino-alkyl sulfonic acid compounds and use in the treatment of subterranean formations |
DE3612538A1 (de) | 1986-04-14 | 1987-10-15 | Dispersa Ag | Stabilisierung von quecksilberhaltigen konservierungsmitteln in augentropfen |
DE3612537C1 (de) | 1986-04-14 | 1987-07-16 | Dispersa Ag | Arzneimittel zur Behandlung von Entzuendungen im Auge |
JP2563336B2 (ja) | 1987-06-01 | 1996-12-11 | エーザイ株式会社 | 角膜透過促進点眼剤 |
US5639481A (en) * | 1994-10-17 | 1997-06-17 | Symbollon Corporation | Method for the therapeutic treatment of a mammalian eye using an admixed composition containing free molecular iodine |
US5849291A (en) * | 1994-10-17 | 1998-12-15 | Symbollon Corporation | Opthalmic non-irritating iodine medicament |
US5603929A (en) * | 1994-11-16 | 1997-02-18 | Alcon Laboratories, Inc. | Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds |
US5558876A (en) * | 1995-03-29 | 1996-09-24 | Alcon Laboratories, Inc. | Topical ophthalmic acidic drug formulations |
US6335335B2 (en) * | 1997-11-05 | 2002-01-01 | Senju Pharmaceutical Co., Ltd. | Prolonged-action eye drop |
KR20010031804A (ko) | 1997-11-05 | 2001-04-16 | 요시다 쇼지 | 지속성 점안제 |
US20040120916A1 (en) * | 2002-12-23 | 2004-06-24 | Advanced Medical Optics, Inc. | Contact lens care compositions, methods of use and preparation which protect ocular tissue membrane integrity |
DE602004013420T2 (de) | 2003-01-21 | 2009-06-04 | Senju Pharmaceutical Co., Ltd. | Wässrige flüssige zubereitung mit 2-amino-3-(4-bromobenzoyl)phenylessigsäure |
EP1654002B2 (en) * | 2003-08-07 | 2014-01-29 | Allergan, Inc. | Compositions for delivery of therapeutics into the eyes |
CN100551378C (zh) * | 2003-11-14 | 2009-10-21 | 千寿制药株式会社 | 包含氨基糖苷类抗生素和溴芬酸的水溶液制剂 |
-
2005
- 2005-11-04 CA CA2560559A patent/CA2560559C/en not_active Expired - Fee Related
- 2005-11-04 PL PL05805529T patent/PL1808170T3/pl unknown
- 2005-11-04 CN CN2005800259636A patent/CN1993118B/zh not_active Expired - Fee Related
- 2005-11-04 KR KR1020067022310A patent/KR101312740B1/ko active IP Right Grant
- 2005-11-04 EP EP05805529A patent/EP1808170B1/en not_active Not-in-force
- 2005-11-04 JP JP2006542445A patent/JP4933897B2/ja not_active Expired - Fee Related
- 2005-11-04 US US10/568,418 patent/US20070021507A1/en not_active Abandoned
- 2005-11-04 KR KR1020137015731A patent/KR20130080061A/ko not_active Application Discontinuation
- 2005-11-04 MX MX2007001172A patent/MX2007001172A/es active IP Right Grant
- 2005-11-04 ES ES05805529T patent/ES2369089T3/es active Active
- 2005-11-04 WO PCT/JP2005/020302 patent/WO2006049250A1/ja active Application Filing
- 2005-11-04 AT AT05805529T patent/ATE520394T1/de active
-
2011
- 2011-12-21 US US13/332,827 patent/US8299124B2/en active Active
-
2012
- 2012-09-14 US US13/616,810 patent/US8518996B2/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02124817A (ja) * | 1988-01-27 | 1990-05-14 | Senju Pharmaceut Co Ltd | 局所投与用炎症性疾患治療剤 |
WO1996019211A1 (fr) * | 1994-12-19 | 1996-06-27 | Taisho Pharmaceutical Co., Ltd. | Gouttes de collyre aux liposomes |
JPH08291065A (ja) * | 1995-04-20 | 1996-11-05 | Santen Pharmaceut Co Ltd | 有機アミンを配合したプラノプロフェン点眼液 |
JPH11335301A (ja) * | 1998-05-21 | 1999-12-07 | Nof Corp | 眼科用製剤 |
JP2002114711A (ja) * | 2000-10-12 | 2002-04-16 | Lion Corp | 外用剤組成物 |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101313899B (zh) * | 2007-06-01 | 2012-02-29 | 北京德众万全药物技术开发有限公司 | 一种含有溴芬酸钠的眼用药物组合物 |
JP2010190837A (ja) * | 2009-02-20 | 2010-09-02 | Kurabo Ind Ltd | logPの決定方法、および該方法に使用される二相系溶媒 |
JP2012532091A (ja) * | 2009-06-30 | 2012-12-13 | 参天製薬株式会社 | ラタノプロストのバイオアベイラビリティを向上させる方法 |
JP2014510018A (ja) * | 2010-12-15 | 2014-04-24 | シェンヤン、シンチ、ファーマシューティカル、カンパニー、リミテッド | ブロムフェナク有機塩、ならびにその製造方法、組成物および使用 |
WO2012099142A1 (ja) * | 2011-01-18 | 2012-07-26 | 千寿製薬株式会社 | 保存効力を有するブロムフェナク水性液剤組成物 |
CN103379904A (zh) * | 2011-01-18 | 2013-10-30 | 千寿制药株式会社 | 具有保存效能的溴芬酸水性液剂组合物 |
JPWO2012099142A1 (ja) * | 2011-01-18 | 2014-06-30 | 千寿製薬株式会社 | 保存効力を有するブロムフェナク水性液剤組成物 |
US9107888B2 (en) | 2011-01-18 | 2015-08-18 | Senju Pharmaceutical Co., Ltd. | Aqueous liquid bromfenac composition having preservative efficacy |
US9561280B2 (en) | 2011-01-18 | 2017-02-07 | Senju Pharmaceutical Co., Ltd. | Aqueous liquid bromfenac composition having preservative efficacy |
JP2012224628A (ja) * | 2011-04-08 | 2012-11-15 | Rohto Pharmaceutical Co Ltd | ブロムフェナク含有組成物 |
WO2015046281A1 (ja) * | 2013-09-26 | 2015-04-02 | 参天製薬株式会社 | 安定化された2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸含有水性組成物 |
CN110461350A (zh) * | 2017-02-21 | 2019-11-15 | 缇尔索卢森公司 | 稳定的肽组合物 |
Also Published As
Publication number | Publication date |
---|---|
US20120095101A1 (en) | 2012-04-19 |
PL1808170T3 (pl) | 2011-12-30 |
KR20070073600A (ko) | 2007-07-10 |
JPWO2006049250A1 (ja) | 2008-05-29 |
US8299124B2 (en) | 2012-10-30 |
ES2369089T3 (es) | 2011-11-25 |
CA2560559A1 (en) | 2006-05-11 |
KR101312740B1 (ko) | 2013-09-27 |
CN1993118A (zh) | 2007-07-04 |
ATE520394T1 (de) | 2011-09-15 |
MX2007001172A (es) | 2007-03-12 |
EP1808170A4 (en) | 2008-03-12 |
US8518996B2 (en) | 2013-08-27 |
KR20130080061A (ko) | 2013-07-11 |
EP1808170A1 (en) | 2007-07-18 |
CA2560559C (en) | 2013-07-02 |
CN1993118B (zh) | 2010-06-16 |
EP1808170B1 (en) | 2011-08-17 |
JP4933897B2 (ja) | 2012-05-16 |
US20130005815A1 (en) | 2013-01-03 |
US20070021507A1 (en) | 2007-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006049250A1 (ja) | 眼内移行性促進水性点眼剤 | |
CA2784492A1 (en) | Non-irritating ophthalmic povidone-iodine compositions | |
EA034839B1 (ru) | Офтальмологический раствор | |
MX2014012158A (es) | Composicion farmaceutica de ibuprofeno y tramadol para uso oftalmico. | |
JP2021518352A (ja) | チモロールを含む医薬組成物 | |
JP6934581B2 (ja) | エピナスチン又はその塩を含有する水性医薬組成物 | |
JP4175801B2 (ja) | 消炎鎮痛点眼剤 | |
AU2013361579B2 (en) | LFA-1 inhibitor formulations | |
WO2005007161A1 (ja) | ピペリジン誘導体を有効成分とする掻痒治療剤 | |
TW201705956A (zh) | 唑系抗真菌藥之對眼瞼皮膚的投與 | |
JP2005047909A (ja) | ピペリジン誘導体を有効成分とする掻痒治療剤 | |
JP7114668B2 (ja) | エピナスチン又はその塩を含有する花粉破裂抑制剤 | |
CN102762195A (zh) | 前列腺素拮抗剂前药的稳定水性组合物及其使用方法 | |
RU2630594C2 (ru) | Офтальмические композиции, содержащие замещенные гамма-лактамы и способы их применения | |
CN104208015A (zh) | 含有曲伏前列腺素和防腐剂的眼部制剂 | |
AU2017235979B2 (en) | Non-irritating ophthalmic povidone-iodine compositions | |
JP6963651B2 (ja) | エピナスチン又はその塩を含有する水性組成物 | |
JP4470393B2 (ja) | 安定である点眼剤 | |
JP2009528390A (ja) | 薬用ラトランキュリン製剤 | |
WO2005053672A1 (ja) | シロミラストまたはその塩を有効成分とする掻痒治療剤 | |
JP2005187458A (ja) | シロミラストまたはその塩を有効成分とする掻痒治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2007021507 Country of ref document: US Ref document number: 10568418 Country of ref document: US |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005805529 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2560559 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2763/KOLNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067022310 Country of ref document: KR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006542445 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 10568418 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/001172 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580025963.6 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005805529 Country of ref document: EP |